| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/06/2002 | CA2429404A1 Use of a compound antagonist of the esm-1 protein for producing a medicine for treating cancer |
| 05/02/2002 | WO2002035356A1 Rapid configuration verification in a multi-component system |
| 05/02/2002 | WO2002035235A2 Net as regulator of angiogenic expression |
| 05/02/2002 | WO2002035231A1 Screening method using a g coupled receptor associated with a specific g protein |
| 05/02/2002 | WO2002034933A2 Methods and compositions for modifying biologically active target molecules |
| 05/02/2002 | WO2002034879A2 Method for introducing antisense oligonucleotides into eucaryotic cells |
| 05/02/2002 | WO2002034761A1 Pyranoside derivatives |
| 05/02/2002 | WO2002034754A2 Benzoxazinone derivatives, their preparation and use |
| 05/02/2002 | WO2002034753A2 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | WO2002034752A1 Antifungal 4-substituted 5,6-dihydro-4h-pyrrolo[1,2-a][1,4]benzodiazepines |
| 05/02/2002 | WO2002034750A1 Process for formulation of antibiotic compounds |
| 05/02/2002 | WO2002034749A1 Polysubstituted imidazopyridines as gastric secretion inhibitors |
| 05/02/2002 | WO2002034747A1 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same |
| 05/02/2002 | WO2002034744A1 Quinazoline derivatives |
| 05/02/2002 | WO2002034743A1 Triazole derivatives and pharmaceutical compositions comprising them |
| 05/02/2002 | WO2002034741A2 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE |
| 05/02/2002 | WO2002034727A2 Treatment of gastrointestinal stromal tumors |
| 05/02/2002 | WO2002034726A2 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | WO2002034721A1 Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors |
| 05/02/2002 | WO2002034719A1 Nitrogenous saturated heterocycle compounds |
| 05/02/2002 | WO2002034718A1 Amide derivatives as nmda receptor antagonists |
| 05/02/2002 | WO2002034716A2 Pyrrolidine modulators of ccr5 chemokine receptor activity |
| 05/02/2002 | WO2002034711A1 Biaryl compounds as serine protease inhibitors |
| 05/02/2002 | WO2002034710A2 Novel intermediates for use in retinoid synthesis |
| 05/02/2002 | WO2002034708A2 Aliphatic amino-substituted demethoxylated hypocrellins and their synthesis |
| 05/02/2002 | WO2002034705A2 C-nitroso compounds and use thereof |
| 05/02/2002 | WO2002034699A2 Mammalian metabolites of a tachykinin receptor antagonist |
| 05/02/2002 | WO2002034303A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/02/2002 | WO2002034293A2 Use of citric acid as antimicrobial agent or enhancer or as anticancer agent |
| 05/02/2002 | WO2002034289A1 Modulating angiogenesis |
| 05/02/2002 | WO2002034284A2 Methods of therapy for hiv infection |
| 05/02/2002 | WO2002034280A2 Use of vanilloid 4 receptor and antagonists or agonists thereof for treating diseases associated with pain |
| 05/02/2002 | WO2002034277A1 Pharmaceutical composition comprising wikstromol and/or matairesinol, its use as hepatoprotectant and process for their isolation from cedrus deodara |
| 05/02/2002 | WO2002034276A2 Use of the association of at least a plant extract of the genus camellia and of at least a carotenoid |
| 05/02/2002 | WO2002034274A1 A composition or rose hip and fish oil for alleviating joint pain and stiffness |
| 05/02/2002 | WO2002034271A1 New composition and method for the treatment of dysglucaemia |
| 05/02/2002 | WO2002034270A1 Treatment of respiratory distress syndrome with powder surfactant composition |
| 05/02/2002 | WO2002034269A1 Method for the preparation of a pharmaceutical composition, and its use |
| 05/02/2002 | WO2002034267A1 Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states |
| 05/02/2002 | WO2002034266A1 Method for inhibiting cataracts |
| 05/02/2002 | WO2002034265A1 Use of 2-hydrazino-1,3-thiazoles as antioxidants |
| 05/02/2002 | WO2002034264A1 Remedies for amyotrophic lateral sclerosis (als) |
| 05/02/2002 | WO2002034263A1 Preventives/remedies for portal hypertension |
| 05/02/2002 | WO2002034262A1 Combination of catechin and quercetin for pharmaceutical or dietary use |
| 05/02/2002 | WO2002034261A1 Compositions for improving lipids in blood |
| 05/02/2002 | WO2002034260A1 6-methoxy-2-naphthylacetic acid prodrugs |
| 05/02/2002 | WO2002034259A1 Combination of fenofibrate and coenzyme q10 for the treatment of endothelial dysfunction |
| 05/02/2002 | WO2002034258A1 Use of hydroxyeicosatetraenoic acid derivatives in intraocular surgery |
| 05/02/2002 | WO2002034257A1 Agents for recoverying from or preventing fatigue in the central nerve system and foods for recoverying from or preventing fatigue |
| 05/02/2002 | WO2002034256A1 Process for producing granular drug preparation containing branched amino acids |
| 05/02/2002 | WO2002034255A1 Granular drug preparations containing branched amino acids and process for producing the same |
| 05/02/2002 | WO2002034254A1 Nateglinide-containing preparations |
| 05/02/2002 | WO2002034253A1 Hair growth stimulant |
| 05/02/2002 | WO2002034252A1 Drug composition comprising dipeptydyl aldehyde derivative |
| 05/02/2002 | WO2002034251A1 Treatment of asthma with lfm analogues |
| 05/02/2002 | WO2002034250A1 Fat emulsions |
| 05/02/2002 | WO2002034249A1 Treatment of pcp addiction and pcp addiction-related behavior |
| 05/02/2002 | WO2002034248A2 METHOD FOR INCREASING TISSUE PERFUSION BY CO-ADMINISTRATION OF AN AGENT THAT INCREASES cGMP SYNTHESIS AND AN AGENT THAT INHIBITS cGMP DEGRADATION |
| 05/02/2002 | WO2002034247A2 Anticancer agents based on regulation of protein prenylation |
| 05/02/2002 | WO2002034246A2 Use of hydroperoxyeicosatetraenoic acid derivatives following refractive surgery |
| 05/02/2002 | WO2002034245A2 Use of tolterodine to treat asthma |
| 05/02/2002 | WO2002034244A2 A combination comprising camptothecin and a stilbene derivative for the treatment of cancer |
| 05/02/2002 | WO2002034243A2 Method for the treatment of neurological and neuropsychological disorders |
| 05/02/2002 | WO2002034242A2 Method for the treatment of neurological and neuropsychological disorders |
| 05/02/2002 | WO2002034241A2 Compounds comprising a phytosterol and/or phytostanol moiety and ascorbis acid and use thereof as weight regulating agents |
| 05/02/2002 | WO2002034240A2 Delayed and sustained release formulations and method of use thereof |
| 05/02/2002 | WO2002034236A2 Lipid formulations for target delivery |
| 05/02/2002 | WO2002034235A1 Topical composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid |
| 05/02/2002 | WO2002034234A2 Methylphenidate modified release formulations |
| 05/02/2002 | WO2002034233A2 Use of an association of a carotenoid and of an isoflavonoid for treating cutaneous symptoms of ageing |
| 05/02/2002 | WO2002034232A2 Use of carotenoids for treating ageing symptoms |
| 05/02/2002 | WO2002034231A2 Use of the association of at least an plant extract of genus rosmarinus and of at least a carotenoid |
| 05/02/2002 | WO2002034206A2 Felodipine transdermal device and methods |
| 05/02/2002 | WO2002034204A2 Calcilytic compounds |
| 05/02/2002 | WO2002034203A2 Novel derivatives of phenyl 4-aminosalicylate and method of making the same |
| 05/02/2002 | WO2002034201A2 Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy |
| 05/02/2002 | WO2002034200A2 Transdermal therapeutic systems comprising photosensitive active substances |
| 05/02/2002 | WO2002034199A2 Medicine intended for treatment of multiple sclerosis |
| 05/02/2002 | WO2002034119A2 Vaccine immunotherapy for immune suppressed patients |
| 05/02/2002 | WO2002034073A2 Compositions containing flavonoids and phlorizin or phloretin |
| 05/02/2002 | WO2002034072A2 Synergistic antioxidant combination of delta tocols and polyphenols |
| 05/02/2002 | WO2002020525A3 Protein tyrosine phosphatase inhibitor |
| 05/02/2002 | WO2002014323A3 Polymorphs of an epothilone analog |
| 05/02/2002 | WO2002013800A3 Method for the prevention and treatment of retinopathy |
| 05/02/2002 | WO2002011737A3 Anti-inflammatory medicament |
| 05/02/2002 | WO2002011710A3 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| 05/02/2002 | WO2002011677A3 Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
| 05/02/2002 | WO2002007726A8 Treatment of movement disorders |
| 05/02/2002 | WO2002006460A3 Masp-2, a complement-fixing enzyme, and uses for it |
| 05/02/2002 | WO2002005822A3 Compositions containing therapeutically active components having enhanced solubility |
| 05/02/2002 | WO2002002121A3 Method for treatment and prevention of mastitis |
| 05/02/2002 | WO2002002103A3 Compositions based on aminoacids, suitable for the treatment of heart failure |
| 05/02/2002 | WO2002002091A3 Methods and compositions for the treatment of alcoholism and alcohol dependence |
| 05/02/2002 | WO2001097785A3 Basic copolymers for the treatment of prion-related-disease |
| 05/02/2002 | WO2001096397A3 Cd154 variants and uses thereof |
| 05/02/2002 | WO2001096283A3 Hiv integrase inhibitors |
| 05/02/2002 | WO2001095877A3 Porous celecoxib matrices and methods of manufacture thereof |
| 05/02/2002 | WO2001093863A3 Pharmaceutical compositions for the treatment of depression or symptoms suggesting depression |
| 05/02/2002 | WO2001092282A3 Methods and compositions for treating flaviviruses and pestiviruses |
| 05/02/2002 | WO2001090121A3 Methods and compositions for treating hepatitis c virus |